Olanzapine: A review of rapid and long-acting parenteral formulations

Drugs of Today

Volumn 46, Issue 3, 2010, Pages 173-181

  Owen, R T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHOLESTEROL; FLUPHENAZINE DECANOATE; GLUCOSE; HALOPERIDOL; HALOPERIDOL DECANOATE; LONG ACTING DRUG; LORAZEPAM; OLANZAPINE; OLANZAPINE PAMOATE; PALIPERIDONE; PLACEBO; RELPREW; RISPERIDONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZYPADHERA;

AGITATION; AKATHISIA; ANTICHOLINERGIC SYNDROME; ANXIETY; AREA UNDER THE CURVE; ASTHENIA; BIPOLAR MANIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFUSION; DELIRIUM; DEMENTIA; DIZZINESS; DRUG COST; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOTENSION; INJECTION PAIN; INJECTION SITE REACTION; INSOMNIA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; ORTHOSTATIC HYPOTENSION; POST HOC ANALYSIS; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLURRED SPEECH; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; UNCONSCIOUSNESS; WEAKNESS; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; SCHIZOPHRENIA;

EID: 77954120697     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.3.1476499     Document Type: Review

References (41)

1. Liebermann, J.A., Stroup, T.S., McEvoy, J.P. et al. Clinical antipsychotic trials of intervention effectiveness (CATIE). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353(12): 1209-23.
2. Weiden, P.J., Kozma, C., Grogg, A., Locklear, J. Partial compliance and risk of rehospitalisation among California Medicaid patients with schizophrenia. Psychiatric Services 2004, 55(8): 886-91.
3. Kane, J.M. Reducing nonadherence: new formulations of antipsychotic medications. Psychiatric Times 2006, 25: 1-3.
4. Patel, M.X. and David, A.S. Why aren't depot antipsychotics prescribed more often and what can be done about it? Adv Psychiatric Treatment 2005, 11: 203-13.
5. Dursun, S. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia. J Psychopharmacol 2005, 10(5, Suppl.1): 3-4.
6. McEvoy, J.P. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006, 67(5, Suppl.): 15s-18s.
7. Ayd, F.J. The depot fluphenazines: a reappraisal after 10 years clinical experience. Am J Psychiatry 1975, 132(5): 491-500.
8. Citrome, L. Patient perspectives in the development and use of long acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. Patient Preference and Adherence 2009, 3: 345-55.
9. Zyprexa Powder For Solution For Injection. Summary of Product Characteristics. http://emc.medicines.org.uk/medicine/7284/SPC/ Zyprexa+Powder+for+Solution+for+Injection (Accessed 9 March 2010).
10. Citrome, L. Comparison of intramuscular ziprasidone, olanzapine or aripiprazole for agitation, a quantitative review of efficacy and safety. J Clin Psychiatry 2007, 68(12): 1876-18.
11. Zyprexa Relprevv US Prescribing Information. http://pi.lilly.com/us/ zyprexa-relprevv.pdf85 (Accessed 9 March 2010).
12. European Medicines Agency Assessment report for Zypadhera 2008. http://www.emea.europa.eu/human-docs/PDFs/EPAR/Zypadhera/H-890-en6.pdf (Accessed 9 March 2010).
13. Kurtz, D., Bergstrom, R., McDonnell, D.P., Mitchell, M. Pharmacokinetics (PK) of multiple doses of olanzapine long-acting injection (OLAI), an intramuscular (IM) depot formulation of olanzapine (OLZ) in stabilized patients with schizophrenia. Biol Psychiatry 2008, 63(7, Suppl. 1): Abst. 909.
14. Callaghan, J.T., Bergstrom, R.F., Ptak, L.R., Beasley, C.M. Olanzapine, pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinetics 1999, 37(3): 177-93.
15. Data on File. Eli Lilly UK
16. Mamo, D., Kapur, S., Keshavan, M. et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008, 33(2): 298-304.
17. Tauscher, J., Jones, C., Remington, G., Zipursky, R.B., Kapur, S. Significant dissociation of brain and plasma kinetics of antipsychotics. Mol Psychiatry 2002, 7(3): 317-21.
18. Lauriello, J., Lambert, T., Andersen, S., Lin, D., Taylor, C.C., McDonnell, D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008, 69(5): 790-99.
19. Kane, J.M., Detke, H.C., Naber, D. et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010, 167(2): 181-9.
20. rd American psychiatric association, San Francisco, CA, USA, May 16-21 2009. Abst. NR1-060.
21. Kalali, A. Patient satisfaction with, and acceptability of, atypical antipsychotics. Curr Med Res Opin 1999, 15(2): 135-7. (Pubitemid 29306745)
22. Zyprexa olanzapine pamoate Briefing Document. http://www.fda.gov/ohrms/ dockets/ac/08/briefing/2008-4228b1-03-Lilly.pdf (Accessed 9 March 2010).
23. rd American Psychiatric association, San Francisco, CA, USA, 2009. Abst. NR-023.
24. Breier, A., Meehan, K., Birkett, M. et al. A double-blind, placebo-controlled, dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002, 59(5): 441-8.
25. Wright, P., Birkett, M., David, S.R. et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001, 158(7): 1149-51.
26. Meehan, K., Zhang, F., David, S. et al. A double-blind, randomized comparison of short-acting intramuscular olanzapine, short-acting intramuscular lorazepam and intramuscular placebo in acutely agitated patients diagnosed with mania associated with bipolar disorder. J Clin Psychopharmacol 2001, 21: 389-97.
27. Meehan, K., Wang, H., David, S.R. et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002, 26(4): 494-504.
28. Battaglia, J., Houston, J.P., Ahl, J., Meyers, A.L., Kaiser, C.J. A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24 hours intramuscular treatment in acutely agitated adult patients with schizophrenia. Clin Ther 2005, 27(10): 1612-8.
29. Wright, P., Meehan, K., Birkett, M. et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clint Ther 2003, 25(5): 1420-8.
30. Battaglia, J., Lindberg, S.R., Alaka, K., Meehan, K., Wright, P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003, 21(3): 192-8.
31. Chandrasena, R., Dvorakova, D., Lee, S.I. Intramuscular olanzapine versus intramuscular short-acting antipsychotics: safety, tolerabilility and the switch to oral antipsychotic medication in patients with schizophrenia or mania. Int J Clin Pract 2009, 63(8): 1249-58.
32. Castle, D.J., Udristoiu, J., Kim, C.Y. et al. Intramuscular olanzapine versus short acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. World J Biol Psychiatry 2009, 10(1): 43-53.
33. Freeman, D.J., DiPaula, B.A., Love, C. Intramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: a cost minimization study. Pharmacotherapy 2009, 29(8): 930-6.
34. Raveendran, N.S., Tharyan, P., Alexander, J., Adams, C.E. et al. Rapid tranquillization in psychiatric emergency settings in India: pragmatic randomized controlled trial of intramuscular olanzapine versus intramuscular haloperidol and promethazine. Br med J 2007, 335 (7625) 865. Epub.
35. Damsa, C., Adam, E., Lazignac, C. et al. A naturalistic study of consecutive agitated emergency department patients treated with intramuscular olanzapine prior to consent. Am J Psychiatry 2008, 165(4): 535-6.
36. Centorrino, F., Meyers, A.L., Ahl, J. et al. An observational study of the efficacy and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder. Hum Psychopharmacol 2007, 22(7): 455-62.
37. San, L., Arranz, B., Querejeta, I., Barrio, S., De La Gundera J., Perez, V. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. Eur Psychiatry 2006, 21(8): 539-43.
38. rd American Psychiatric Association, San Francisco, CA, USA, May 16-21 2009. Abst. NR1-011.
39. Zyprexa IntraMuscular Injection US Prescribing Information. http://pi.lilly.com/us/zyprexa-pi.pdf (accessed 9 March 2010).
40. Satterthwaite, T.D., Wolf, D.H., Rosenheck, R.A., Gur, R.E., Caroff, S.N. A meta-analysis of the risk of extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 2008, 69 (12): 1869-79.
41. Marder, S.R., Soraburu, S., Dunayevich, E. et al. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with acute agitation. J Clin Psychiatry 2010, Feb 9 Epub ahead of print.